Page last updated: 2024-11-03

proadifen and Acute Promyelocytic Leukemia

proadifen has been researched along with Acute Promyelocytic Leukemia in 1 studies

Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.

Research Excerpts

ExcerptRelevanceReference
"This proadifen-MTX synergism was also mediated by the inhibition of various cellular proteins engaged in apoptosis, including Mc-1, Bcl-xL, survivin and activation of procaspase-3."1.42Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells. ( Fedoročko, P; Hiľovská, L; Jendželovská, Z; Jendželovský, R; Kovaľ, J, 2015)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hiľovská, L1
Jendželovský, R1
Jendželovská, Z1
Kovaľ, J1
Fedoročko, P1

Other Studies

1 other study available for proadifen and Acute Promyelocytic Leukemia

ArticleYear
Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells.
    International journal of oncology, 2015, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting,

2015